PROBIOTIX HEALTH LS-05 (F:X90) — Market Cap & Net Worth
Market Cap & Net Worth: PROBIOTIX HEALTH LS-05 (X90)
PROBIOTIX HEALTH LS-05 (F:X90) has a market capitalization of $13.59 Million (€11.63 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #26274 globally and #2267 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PROBIOTIX HEALTH LS-05's stock price €0.07 by its total outstanding shares 158166666 (158.17 Million). Review X90 total liabilities to assess the company's total debt and financial obligations.
PROBIOTIX HEALTH LS-05 Market Cap History: 2022 to 2026
PROBIOTIX HEALTH LS-05's market capitalization history from 2022 to 2026. Data shows change from $38.83 Million to $13.59 Million (-79.17% CAGR).
PROBIOTIX HEALTH LS-05 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PROBIOTIX HEALTH LS-05's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.09x
PROBIOTIX HEALTH LS-05's market cap is 6.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $11.93 Million | $1.67 Million | -$747.00K | 7.13x | N/A |
| 2024 | $11.46 Million | $1.88 Million | -$847.00K | 6.09x | N/A |
Competitor Companies of X90 by Market Capitalization
Companies near PROBIOTIX HEALTH LS-05 in the global market cap rankings as of June 19, 2026.
Key companies related to PROBIOTIX HEALTH LS-05 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
PROBIOTIX HEALTH LS-05 Historical Marketcap From 2022 to 2026
Between 2022 and today, PROBIOTIX HEALTH LS-05's market cap moved from $38.83 Million to $ 13.59 Million, with a yearly change of -79.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.59 Million | +16.67% |
| 2025 | €11.65 Million | +1.61% |
| 2024 | €11.46 Million | -3.88% |
| 2023 | €11.93 Million | -69.29% |
| 2022 | €38.83 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of PROBIOTIX HEALTH LS-05 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.59 Million USD |
| MoneyControl | $13.59 Million USD |
| MarketWatch | $13.59 Million USD |
| marketcap.company | $13.59 Million USD |
| Reuters | $13.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PROBIOTIX HEALTH LS-05
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and … Read more